Recent trials unveil significant advances in cancer treatment with immunotherapy drug Tecentriq, showing a 50% reduction in ...

Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread ...

Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard ...

It might sound basic, but data shows that focusing on healthy food and structured exercise might help patients with cancer live longer or respond to therapy. Other cancer news reports on immunotherapy ...

The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer.' ...

Adding atezolizumab to chemo in stage 3 dMMR colon cancer halves the risk of recurrence, marking a major step in precision ...

New phase 1 findings highlight promise of first-in-class bispecific antibody fusion for advanced colorectal cancer.